373 Inverness Parkway, Suite 206
106 articles with Aytu BioScience
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering for total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Aytu BioScience, Inc. announced the pricing of an underwritten public offering with expected total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
Aytu BioScience today provided an overview of its business, including the Company's operational and financial results for its fiscal second quarter ended December 31, 2017.
The Company will review recent accomplishments and provide an overview of its business and growth strategy.
Mr. Green is a highly accomplished CFO, who brings an extensive array of financial, accounting, and operational experience to Aytu.
As per the terms of the License and Supply Agreement with Aytu, revenues associated with these orders will be recognized on delivery of the product to Aytu, with additional revenues recognized quarterly based on a percentage of net sales.
Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date.
Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
The Company will host a live conference call and webcast today at 4:30 p.m. ET. Conference call details are provided at the end of this press release.
Aytu BioScience Receives Market Approval From the Australian Therapeutic Goods Administration for the MiOXSYS System for Male Infertility
MiOXSYS has been approved by the TGA as an aid in the diagnostic assessment of semen quality for patients undergoing male infertility evaluation.
Live Conference Call and Webcast Scheduled for November 9, 2017, at 4:30 p.m. ET
Aytu BioScience Presents Clinical Findings for its MiOXSYS System at 73rd Annual Meeting of the ASRM
Aytu BioScience today announced that it presented six posters demonstrating the clinical potential of MiOXSYS, the company's rapid in vitro diagnostic system for the qualitative measurement of static oxidation-reduction potential (sORP) in human semen, to be used as an aid in the diagnosis of infertility in males.
Aytu BioScience today provided an update on the ongoing launch of Natesto in the U.S.
Aytu BioScience today announced that its shares of common stock were approved for listing on The NASDAQ Capital Market.